Last deal

$26M

Amount

Grant

Stage

16.10.2018

Date

3

all rounds

$29.15M

Total amount

date founded

Financing round

General

About Company
Stratatech Corporation develops cell-based and tissue-engineered skin substitute products for therapeutic and research applications.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2000

Number of employees

Company Type

For Profit

Last funding type

Grant

IPO status

Private

Description

The regenerative medicine company specializes in human tissue substitutes generated with NIKS keratinocytes and cells derived from them for biological therapies. Its products include StrataGraft skin tissue, which promotes wound healing by the patient's own cells and improve the wound bed to receive autografts, and ExpressGraft skin tissue, a genetically enhanced tissue that produces various levels of natural wound healing and antimicrobial factors. The company's substitute is made of human cells that act as a temporary wound cover, fighting bacterial infections and promoting healing by a patient's own cells, providing easy care for chronic, non-healing wounds. Founded in 2000 and based in Madison, Wisconsin.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Primecell

Primecell

PrimeCell Therapeutics is a Czech biotechnology company focused on regenerative medicine and advanced therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Prague, Czechia
Rege Nephro

Rege Nephro

Rege Nephro develops therapeutic drugs for renal failure patients.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Kyoto, Japan

total rounds

2

total raised

$3.3M
Targazyme

Targazyme

Targazyme is a bio-pharmaceutical company that develops and commercializes breakthrough products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Carlsbad, CA, USA

total rounds

1

total raised

$2.5M
Novadip Biosciences

Novadip Biosciences

Novadip Biosciences develops innovative stem cell-based therapies for regenerative medicine.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Mont-Saint-Guibert, Belgium

total rounds

4

total raised

$92.8M
M&A Details
1

Transaction name

Acquired by

Mallinckrodt

announced date

10.08.2016

Financials

Funding Rounds
3
3

Number of Funding Rounds

$29.15M

Money Raised

Their latest funding was raised on 16.10.2018. Their latest round Grant

Date 
Funding Round 
Investors 
Money Raised 
Lead 
16.10.2018
$26M
15.09.2015
$150K
06.04.2010
$3M
Co-Investors

People

Founders
1
B. Lynn Allen-Hoffmann
B. Lynn Allen-Hoffmann

B. Lynn Allen-Hoffmann

Dr. Allen-Hoffmann is the Founder, CEO, Chief Science Officer and a Director of Stratatech. Dr. Allen-Hoffmann obtained her doctorate from Cornell University and trained with Dr. James Rheinwald at Harvard Medical School. Dr. Allen-Hoffmann has been Professor of Pathology at the University of Wisconsin Medical School since 1988 and has received continuous funding from the National Institutes of Health for her research program. She has extensive leadership experience and previously directed a multi-college Center at the University of Wisconsin-Madison. Recently Dr. Allen-Hoffmann’s research and business contributions have been recognized by the 2005 Harold Rusch Translational Research Award and 2006 TEMPO Business Women of Distinction.

current job

Stratatech Corporation
Stratatech Corporation

organization founded

1

B. Lynn Allen-Hoffmann

Employee Profiles
8

Allen Comer

Senior Director - Research, Strategy, and Innovation

Andy Bovre

Validation engineer

Cindy Ballweg

Cindy Ballweg

Director Finance & Administration and Treasurer

Russell R. Smestad

Russell R. Smestad

President

B. Lynn Allen-Hoffmann

B. Lynn Allen-Hoffmann

CEO

Activity

Recent News
0